A Case of Paradoxical Flare of Pustular Psoriasis after Ustekinumab Therapy.
- Author:
In Hye KANG
1
;
Min Kyung SHIN
;
Mu Hyoung LEE
;
Ki Heon JEONG
Author Information
1. Department of Dermatology, School of Medicine, Kyung Hee University, Seoul, Korea. mdfamily@hanmail.net
- Publication Type:Case Report
- Keywords:
Adalimumab;
Biological products;
Psoriasis;
Ustekinumab
- MeSH:
Adalimumab;
Adult;
Arthritis, Psoriatic;
Biological Products;
Female;
Glycogen Storage Disease Type VI;
Humans;
Injections, Subcutaneous;
Interleukin-12;
Interleukin-23;
Psoriasis*;
Ustekinumab*
- From:Korean Journal of Dermatology
2018;56(9):548-551
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Biologics are the most advanced treatment for psoriasis. Ustekinumab, one of the biologics for psoriasis, is a human monoclonal antibody that binds to the p40 subunit of interleukin-12 and interleukin-23. A 41-year-old woman with a 17-year history of plaque psoriasis and psoriatic arthritis presented with worsening lesions. The patient had previously been treated with a number of topical and systemic medications and narrow band ultraviolet B. However, none of the treatments consistently controlled her disease. Thus, treatment with ustekinumab 45 mg via subcutaneous injection was initiated. Approximately 7 days after the first treatment, she experienced a flare with generalized pustules in her whole body. The condition was controlled with systemic steroid treatment. The patient was subsequently treated with adalimumab, and improvement in her plaque and pustular lesions was noted. Herein, we report a case of psoriasis that flared up after ustekinumab therapy, which was accompanied by a morphological change from plaque to pustular lesions.
